Press release
Catalyst Biosciences Announces Poster Presentations at the EAHAD 2021 Virtual Congress
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced two e-poster presentations at the
About this update from Gyre Therapeutics, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced two e-poster presentations at the European Association for Haemophilia and Allied Disorders (EAHAD) Virtual Congress being held on February 3 - 5, 2021. Poster presentation details Poster Title: Subcutaneous Marzeptacog Alfa (Activated) is effective for on-demand treatment of spontaneous bleeding in hemophilia A rats Presenter: Tom Knudsen, DVM, Ph.D., vice president of translational research, Catalyst Biosciences Program number: ABS027 Date/Time:Poster available starting at 6 pm CET on February 2, through August 5, 2021 Poster Title:Subcutaneous Marzeptacog Alfa (Activated) is effective for on-demand treatment of spontaneous bleeding in dogs with Hemophilia A Presenter:Howard Levy, M.B.B.Ch., Ph.D., M.M.M., chief medical officer, Catalyst Biosciences Program number: ABS028 Date/Time:Poster available starting at 6 pm CET on February 2, through August 5, 2021 A copy of the presentation materials can be accessed on the Events and Presentations section of the Catalyst website (www.catalystbiosciences.com) once the presentations conclude. About Catalyst Biosciences, the Protease Medicines companyCatalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform has generated two late-stage clinical programs, including MarzAA, a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. Our complement pipeline includes a pre-clinical program partnered with Biogen for dry age-related macular degeneration, an improved complement factor I protease for SQ replacement therapy in patients with CFI deficiency and C4b-degraders designed to target disorders of the classical complement pathway as well as other complement programs in development. Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about Catalyst’s product candidates and the benefits of its protease engineering platform. Actual results or events could differ materially from the plans...